Cipla share price today: The pharma major reported a 49% increase in net profit, reaching Rs 1,571 crore (Image: Reuters) Cipla shares soared 10% to an intraday high of Rs 1,560.05 after USFDA ...

Stock Market Today: Cipla share price gained 10% in the morning trade on Thursday, October 31 after the company announced that its Goa facility has been classified as Voluntary Action Indicated (VAI).

Cipla said that the United States Food and Drug Administration (US FDA) has conducted an inspection at the company's manufacturing facility in Verna, Goa, India from 6th to 17th April 2026.

Brokerages on the Street have taken a U-turn with their growth outlook for Cipla just a few days after the company released its July-September numbers. The culprit here is the surprise regulatory ...

Shares of Cipla slipped over 3% today after the pharma firm said US Food and Drug Administration (USFDA) inspected its manufacturing facility in Goa from June 10 to June 21 this year. The pharma firm ...

The long haul of regulatory issues at Cipla's Goa manufacturing site had resulted in multiple delays for Abraxane's anticipated launch, prompting analysts to project it as a potential opportunity only ...

Cipla Ltd's shares skyrocketed by 9.88% today, reaching an intraday high of ₹1,557.45 on the Bombay Stock Exchange (BSE). As ...

When an inspection of Cipla’s sterile injectable plant in Goa, India, went badly last fall, it appeared pretty certain a warning letter would follow. The inspection report, after all, went on for 38 ...

Nomura India maintains 'Buy' rating on Cipla with Rs 1,780 target by March 2026. Cipla's Goa site receives USFDA approval for gAbraxane, paving way for FY26 launch. Launch expected in 1HFY26, despite ...

https://www.thehindubusinessline.com/markets/cipla-stock-rises-nearly-2-after-usfda-grants-vai-status-to-goa-plant/article68828574.ece Copy Shares of Cipla gained ...